Asia Pacific Implantable Cardiac Monitors Market Size, Share, and COVID-19 Impact Analysis, By Indication (Cardiac Arrythmias, Atrial Fibrillation, and Epilepsy and Unexplained Falls), By End-User (Hospitals & Clinics, Home Settings, Ambulatory Surgical Centers, and Others), and Asia Pacific Implantable Cardiac Monitors Market Insights, Industry Trend, Forecasts to 2035.
Industry: HealthcareAsia Pacific Implantable Cardiac Monitors Market Insights Forecasts to 2035
- The Market Size is Expected to Grow at a CAGR of around 8.85% from 2025 to 2035
- The Asia Pacific Implantable Cardiac Monitors Market Size is Expected to hold a significant share by 2035
Get more details on this report -
The Asia Pacific Implantable Cardiac Monitors Market is anticipated to hold a significant share by 2035, growing at a CAGR of 8.85% from 2025 to 2035. The growing prevalence of atrial fibrillation, driven by an aging population as well as technological advancements in cardiac monitoring devices, is propelling the implantable cardiac monitors market in the Asia Pacific region.
Market Overview
The Asia Pacific implantable cardiac monitors market is the industry encompassing the development, manufacturing, and sales of small devices that are implanted under the skin to continuously monitor a patient’s heart rhythm. Implantable cardiac monitors (ICM) are used for long-term monitoring of a patient’s heart electrical activity to detect irregular heart rhythms (arrhythmias). ICMs are recommended to be used for patients with unexplained syncope and for those suspected to have atrial fibrillation (AF). There is a growing prevalence of atrial fibrillation and myocardial infarction, due to factors like unhealthy lifestyle, which is anticipated to drive the demand for implantable cardiac monitors to ensure that the patient has a well-functioning heart. Introduction of remote monitoring solutions, along with the regulatory support and reimbursement policies, is escalating the market opportunities for implantable cardiac monitors.
Report Coverage
This research report categorizes the market for the Asia Pacific implantable cardiac monitors market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Asia Pacific implantable cardiac monitors market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Asia Pacific implantable cardiac monitors market.
Asia Pacific Implantable Cardiac Monitors Market Report Coverage
Report Coverage | Details |
---|---|
Base Year: | 2024 |
Forecast Period: | 2025-2035 |
Forecast Period CAGR 2025-2035 : | 8.85% |
Historical Data for: | 2020-2023 |
No. of Pages: | 177 |
Tables, Charts & Figures: | 101 |
Segments covered: | By Indication, By End-User and COVID-19 Impact Analysis |
Companies covered:: | Abiomed, Inc., Abbott Laboratories, Boston Scientific Corporation, Reliant Heart, Inc., Astellas Pharma inc., Biotronik SE & Co. KG, Agilent Technologies, Inc., Berlin Heart GmbH, Schiller AG, Jarvik Heart, Inc., Others, and others key players |
Pitfalls & Challenges: | COVID-19 Empact, Challenges, Future, Growth, & Analysis |
Get more details on this report -
Driving Factors
The increasing prevalence of atrial fibrillation due to an aging population and lifestyle factors like a sedentary lifestyle is responsible for driving the market demand for implantable cardiac monitoring devices. For instance, atrial fibrillation is the most common type of cardiac arrhythmia affecting over 1.4 million new patients each year. Innovation in heart monitoring solutions, such as Heartnet Console, as well as advanced digital platforms that empower real-time heart monitoring for early detection and personalized care, are propelling the market growth.
Restraining Factors
The increased cost of devices, along with inadequate reimbursement policies, especially in the developing countries of Asia Pacific region, is challenging the market growth. The preference for drugs over devices for treatment is hindering the market demand for implantable cardiac monitors.
Market Segmentation
The Asia Pacific implantable cardiac monitors market share is classified into indication and end-user.
- The cardiac arrythmias segment dominated the market with a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.
The Asia Pacific implantable cardiac monitors market is segmented by indication into cardiac arrythmias, atrial fibrillation, and epilepsy and unexplained falls. Among these, the cardiac arrythmias segment dominated the market with a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. It includes subcutaneous implantable cardioverter defibrillators (S-ICDs), which are used in people with fast heart rhythms and are implanted under the skin rather than through veins. The growing prevalence of cardiac arrhythmias, along with an increasing awareness about the benefits of long-term cardiac monitoring, is contributing to driving the market.
- The hospitals & clinics segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.
The Asia Pacific implantable cardiac monitors market is segmented by end-user into hospitals & clinics, home settings, ambulatory surgical centers, and others. Among these, the hospitals & clinics segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. Implantable cardiac monitoring devices allow healthcare providers to remotely monitor, track, and assess data of patients’ heart conditions. The use of these devices in hospitals & clinics for acute care, non-acute care, and non-treatment purposes is propelling the market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Asia Pacific implantable cardiac monitors market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Abiomed, Inc.
- Abbott Laboratories
- Boston Scientific Corporation
- Reliant Heart, Inc.
- Astellas Pharma inc.
- Biotronik SE & Co. KG
- Agilent Technologies, Inc.
- Berlin Heart GmbH
- Schiller AG
- Jarvik Heart, Inc.
- Others
Recent Developments:
- In August 2022, Singapore’s Health Service Authority approved for commercialization an AI-enabled implantable cardiac device by Hydrix Medical, the medical technology business of ASX-listed company Hydrix.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Market Segment
This study forecasts revenue at Asia Pacific, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Asia Pacific Implantable Cardiac Monitors Market based on the below-mentioned segments:
Asia Pacific Implantable Cardiac Monitors Market, By Indication
- Cardiac Arrythmias
- Atrial Fibrillation
- Epilepsy and Unexplained Falls
Asia Pacific Implantable Cardiac Monitors Market, By End-User
- Hospitals & Clinics
- Home Settings
- Ambulatory Surgical Centers
- Others
Need help to buy this report?